A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis.
10.4078/jrd.2013.20.6.361
- Author:
Sang A CHOI
1
;
Seung Geun LEE
;
Sang Heon SONG
;
Ji Min KIM
;
Hye Yoon JANG
;
Woo Jin JUNG
;
Jong Hyun CHOI
;
Young Eun PARK
;
Seong Hu PARK
;
Joung Wook LEE
;
Jun Hee LEE
;
Seung Hoon BAEK
;
Geun Tae KIM
Author Information
1. Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
- Publication Type:Case Report
- Keywords:
Ankylosing spondylitis;
End-stage renal disease;
Peritoneal dialysis;
Tumor necrosis factor-alpha
- MeSH:
Adult;
Anti-Inflammatory Agents, Non-Steroidal;
Antirheumatic Agents;
Humans;
Immunoglobulin G;
Kidney Failure, Chronic;
Male;
Metabolism;
Necrosis;
Peritoneal Dialysis*;
Pharmacokinetics;
Receptors, Tumor Necrosis Factor;
Renal Insufficiency;
Spondylitis, Ankylosing*;
Tumor Necrosis Factor-alpha;
Etanercept
- From:Journal of Rheumatic Diseases
2013;20(6):361-363
- CountryRepublic of Korea
- Language:English
-
Abstract:
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFalpha) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFalpha agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFalpha agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
